Ethical and Practical Dimensions of Patient Safety in (Es)ketamine Therapy: German Clinical Insights

Empirical Findings: Patient Safety and Vulnerability in (Es)ketamine Therapy

A 2026 qualitative study conducted in German psychiatric clinics demonstrates that patient safety in (es)ketamine—both intravenous ketamine and intranasal esketamine (Spravato®)—is shaped by more than clinical protocols, with vulnerability and felt safety emerging as central themes. Through semi-structured interviews with 14 patients and 10 clinicians, the research identifies three types of pre-treatment concerns, three overlapping modes of experiencing safety, and three distinct models of ketamine’s mechanism of action, all influencing the care requirements for each patient.

Patients described heightened vulnerability during treatment, characterized by reduced self-advocacy and self-regulation. Therapeutic presence, active physical grounding, and structured post-acute support—termed "landing aid"—were repeatedly cited as essential for feeling safe. Notably, these elements are not always explicit in existing protocols or guidelines, underlining a gap between regulatory minimums and the lived experience of care.

Mechanisms: Relational Safety and Divergent Expectations

Safety in (es)ketamine therapy is relationally constructed, with clinician behavior and the therapeutic environment playing decisive roles. The study reveals a misalignment between clinician and patient expectations: clinicians often view ketamine as a catalyst for psychological transformation, while patients typically seek temporary relief or symptom management. This divergence can lead to mismatched preparation, integration, and support, potentially undermining both safety and efficacy.

Patients’ sense of safety depended not only on the technical administration of the drug but also on the clinician’s presence and responsiveness during and after the session. Structured post-acute support—such as a dedicated debrief or transition period—was highlighted as a modifiable, low-resource intervention with outsized impact on patient well-being. This insight, rarely emphasized in formal protocols, points to a concrete opportunity for improving care standards with minimal additional burden.

Policy and Research Implications: Beyond Protocols to Flexible, Patient-Centered Care

The study’s findings challenge the adequacy of one-size-fits-all protocols for (es)ketamine therapy, advocating for a patient-centered approach that recognizes the ethical significance of felt safety and relational vulnerability. This has direct implications for policymakers, professional bodies, and institutional review boards (IRBs) tasked with developing or updating standards of care and informed consent procedures.

Recommendations derived from the study are graded by strength and include: ensuring therapeutic presence throughout the session, providing active grounding techniques, and establishing structured post-acute support. Importantly, one recommendation was withheld where the vulnerability analysis indicated a risk, illustrating the need for nuanced, context-dependent guidance rather than universal mandates.

For researchers, the study underscores the importance of further empirical work in larger and more diverse samples to confirm and refine these findings. It also suggests that future trials and implementation studies should explicitly measure both clinical and felt safety as distinct outcomes, and that qualitative data should inform regulatory and ethical frameworks.

Risks, Unknowns, and the Limits of Current Evidence

While the study provides valuable insights, its exploratory nature and small sample size (14 patients, 10 clinicians) limit the generalizability of its conclusions. The research was conducted exclusively in German psychiatric settings, which may differ in staff training, patient population, and regulatory oversight from other jurisdictions. There is also a risk that overemphasis on flexible, patient-centered care could inadvertently introduce variability that complicates standardization and oversight, especially in less-resourced or less-experienced clinics.

A critical, under-discussed failure mode is the potential for minor lapses in clinician behavior or inadequate post-acute support to undermine the ethical basis for informed consent, given the patient’s heightened dependency during altered states. This risk is modifiable, but only if recognized and systematically addressed in training and supervision.

Looking Forward: Building Ethical, Responsive Models of Psychedelic Care

The study’s findings point toward a future in which ethical and practical demands for patient safety in (es)ketamine and other consciousness-altering therapies are met not only through technical competence but through relational, responsive care models. As regulatory agencies, professional societies, and clinics in Germany and beyond consider updates to standards and protocols, integrating these empirical-ethical insights will be essential for both patient protection and the legitimacy of the field.

Ultimately, the research highlights that safety in (es)ketamine therapy is not simply a matter of avoiding adverse events but of actively fostering an environment in which vulnerable patients can consent, participate, and recover with dignity. This calls for ongoing dialogue between patients, clinicians, and policymakers, and for research designs that capture the full spectrum of safety—clinical, felt, and ethical—across diverse treatment settings.

How we research: This article was written and reviewed by Dr. Anna Richter, PhD (bioethics, University of Heidelberg), on 2026-10-10. Primary source: OpenAlex W7221052695; see also the Spravato® (esketamine) official information and BfArM (German Federal Institute for Drugs and Medical Devices) for regulatory context.